Cogent Biosciences, Inc. — Filing identity and period
Important identity discrepancy: The supplied filing is a Form 10-Q filed by Unum Therapeutics Inc. (Nasdaq: UMRX), not Cogent Biosciences, Inc. It covers the quarter and nine months ended September 30, 2019, and was signed November 12, 2019. Verify that this is the intended filing before relying on the figures below.
Business context and financial results
Unum was a clinical-stage cell-therapy company developing ACTR and BOXR platforms for cancer. It had no approved products and generated no product-sales revenue; reported revenue was from its Seattle Genetics collaboration.
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Collaboration revenue | $1.0 million | $2.0 million | $7.2 million | $5.9 million |
| Research and development | $10.3 million | $10.3 million | $33.4 million | $27.5 million |
| General and administrative | $2.7 million | $2.4 million | $8.3 million | $5.4 million |
| Total operating expenses | $13.1 million | $12.6 million | $41.6 million | $32.9 million |
| Net loss | $11.9 million | $10.2 million | $34.1 million | $25.9 million |
| Basic and diluted loss per share | $0.39 | $0.34 | $1.12 | $1.12 |
Margins: Not meaningful as the company had no product sales and remained loss-making. Revenue was recognized under the collaboration using a cost-to-cost measure of progress.
Cash, liquidity, and debt
- At September 30, 2019, cash and cash equivalents were $45.9 million; restricted cash was another $1.3 million. Marketable securities were zero, down from $22.9 million at year-end 2018.
- Working capital was reported as approximately $23.5 million. Current assets were $48.0 million and current liabilities $24.4 million.
- Operating cash use for the first nine months was $33.1 million, compared with $23.5 million in 2018. Investing activities provided $23.2 million, largely from marketable-security maturities; financing provided $0.1 million. Cash, cash equivalents, and restricted cash declined $9.8 million.
- No term loans had been drawn under the Pacific Western Bank facility. Up to $15.0 million was available; borrowings would be secured by substantially all assets except intellectual property. The filing reports no other debt outstanding.
- The balance sheet includes $6.4 million of operating lease liabilities. The office and laboratory lease runs through April 2023.
Changes, outlook, and material developments
- Compared with Q3 2018, quarterly collaboration revenue fell about 50% and net loss widened by $1.8 million; management attributed the revenue decline mainly to the timing of collaboration work. For the first nine months, revenue rose about 22%, while operating expenses increased about 26% and net loss widened by $8.2 million.
- Management attributed higher year-to-date R&D costs to clinical activity and increased headcount, including spending on ACTR707 and the ACTR707/trastuzumab solid-tumor trial. Higher G&A reflected staffing and public-company, professional, and insurance costs.
- Management forecast cash and cash equivalents would fund operating and capital needs into early 2021, excluding available borrowings. The financial-statement note separately says cash was expected to cover at least 12 months from issuance; these runway statements use different wording and should be reconciled. Management also said additional funding would be needed for planned R&D.
- In November 2019, after the quarter-end, Unum announced a strategic shift toward solid tumors and platform development, with hematologic programs de-prioritized. It identified completing the ACTR707/HER2+ Phase 1 trial, advancing BOXR1030 toward an anticipated late-2020 IND filing, and expanding BOXR research as priorities. These are plans, not guaranteed outcomes.
- Also in November, Unum and Seattle Genetics suspended further development and dose escalation in the ATTCK-17-01 multiple-myeloma trial while reviewing next steps. The filing estimated $40.7 million allocated to remaining collaboration performance obligations before the suspension; the accounting impact was to be assessed in Q4 2019.
- The ATTCK-20-2 ACTR087/rituximab trial was on a partial FDA clinical hold following a serious adverse event that included neurotoxicity and culminated in a fatal septic-shock event reported by the investigator as related to ACTR087. ACTR707/rituximab had shown preliminary activity in a small early-stage trial: an October 2019 cutoff indicated complete responses in 8 of 20 patients across the first four cohorts. These preliminary results are not proof of efficacy.
- There was no formal financial forecast for revenue or earnings. The company warned it might need equity, debt, collaboration, or licensing financing; financing may dilute shareholders or require relinquishing rights. It reported no material legal proceedings and effective disclosure controls as of September 30, 2019.
Most important facts for investors to verify
- Confirm the issuer: the filing identifies Unum Therapeutics Inc., not Cogent Biosciences, Inc.
- Reconcile the stated cash runway—“at least 12 months from issuance” versus “into early 2021”—and assess cash burn after the strategic shift.
- Check the Q4 accounting and revenue consequences of suspending Seattle Genetics collaboration work, including treatment of deferred revenue and remaining obligations.
- Review subsequent clinical and regulatory updates on the ACTR087 partial hold, ACTR707 trials, and Seattle Genetics program suspension; distinguish preliminary small-cohort data from established clinical benefit.
- Assess financing needs, availability and terms of the undrawn $15 million facility, potential dilution, and the facility’s collateral and covenants.